Critical Analysis on the Mechanism of Action (MoA) of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma (MM)‏ by Laura Moreno, Aintzane.

Slides:



Advertisements
Similar presentations
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies by Jutta Deckert, Peter U. Park,
Advertisements

Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma by Joshua Richter, Natalia Neparidze,
New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)‏ by Antonio Palumbo,
Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.
Pathogenesis beyond the cancer clone(s) in multiple myeloma by Giada Bianchi, and Nikhil C. Munshi Blood Volume 125(20): May 14, 2015 ©2015 by.
Lenalidomide augments actin remodeling and lowers NK- cell activation thresholds by Kathryn Lagrue, Alex Carisey, David J. Morgan, Rajesh Chopra, and Daniel.
Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.
Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura by Miguel Hie, Julie Gay, Lionel.
Do HSCs divide asymmetrically?
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)‏ by Antonio Palumbo,
How I treat multiple myeloma in younger patients
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,
TCR-MHC-peptide(s): in vivo veritas
Umbilical cord blood transplantation and cytomegalovirus: posttransplantation infection and donor screening by Maria S. Albano, Patricia Taylor, Robert.
Multiple Myeloma: Interleukin-15 Antagonizes Bone Morphogenetic Protein-Induced Apoptosis and Growth Inhibition. by Magne Rekvig, Anne-Tove Brenne, Torstein.
Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile.
Bone Marrow Mesenchymal Stem Cell (BM-MSC) Release Microvesicles/Exosomes That Incorporate Into Hematopoietic Cells From MDS Patients and May Modify Their.
Platelet Antibody Testing in Idiopathic Thrombocytopenic Purpura
by Taizo Wada, Shepherd H. Schurman, G
Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator by Esther P.M. Tjin, Patrick W.B.
by Venetia Bigley, Laura E. Spence, and Matthew Collin
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma by Shaji K. Kumar, Betsy LaPlant,
T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma by Lotta.
Lytic Replication of Epstein-Barr Virus in the Peripheral Blood: Analysis of Viral Gene Expression in B Lymphocytes During Infectious Mononucleosis and.
Tax fingerprint in adult T-cell leukemia
The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.
Transplants for the elderly in myeloma
How I treat elderly patients with myeloma
by Thomas Rasmussen, Linda Jensen, Lone Honoré, and Hans Erik Johnsen
Nonmyeloablative conditioning for relapsed follicular lymphoma
Mechanisms of HIV-associated lymphocyte apoptosis
Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients by Nicola Giuliani, Francesca Morandi, Sara Tagliaferri, Simona Colla,
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report by Antonio Palumbo, Sara.
FNAIT: the fetus pleads guilty!
Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)
by Daniel W. Bougie, Ana I. Benito, Luis I
by Jonathan N. Hofmann, Linda M. Liao, Michael N
by Wolfram Springer, Alexander von Ruecker, and Roswitha Dickerhoff
by Jessica A. Reese, Xiaoning Li, Manfred Hauben, Richard H
Solitary plasmacytoma of bone and asymptomatic multiple myeloma
Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias by David Gómez-Almaguer, Manuel Solano-Genesta,
Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia by Jose Roman-Gomez, Antonio.
Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
by J. Rodriguez, M. A. Rodriguez, L. Fayad, P. McLaughlin, F. Swan, A
Lymphoma spread? Target CD47-SIRPα!
Bone Turnover Biomarkers Are Useful In Monitoring Myeloma Bone Disease and As Early Predictor Biomarkers For Relapse Disease In Multiple Myeloma by Kay.
How I treat refractory CLL
Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd,
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
Volume 19, Issue 1, Pages (April 2017)
Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma:
by Santosh L. Saraf, Xu Zhang, Tamir Kanias, James P. Lash, Robert E
Volume 19, Issue 1, Pages (April 2017)
Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study.
Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus.
by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther
Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.
Anti-CD20-IL-21 fusokine: the tail wags the dog
Rituximab immunotherapy: it’s getting personal
Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term.
A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.
by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio
by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal
Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease by Paula Rodriguez-Otero,
Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed.
Cold agglutinin disease
Presentation transcript:

Critical Analysis on the Mechanism of Action (MoA) of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma (MM)‏ by Laura Moreno, Aintzane Zabaleta, Diego Alignani, Daniel Ajona, Marta Lasa, Patricia Maiso, Tomas Jelinek, Victor Segura, Jose Antonio Delgado, Paula Rodriguez-Otero, Felipe Prosper, Jesus San Miguel, and Bruno Paiva Blood Volume 128(22):2105-2105 December 2, 2016 ©2016 by American Society of Hematology

Laura Moreno et al. Blood 2016;128:2105 ©2016 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.